November 26, 2019
- Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 15, 2019
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 8, 2019
- Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week
November 7, 2019
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 5, 2019
- Apellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial Results
October 11, 2019
- Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019
September 27, 2019
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 26, 2019
- Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
September 18, 2019
- Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration
September 16, 2019
- Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes
Displaying 1 - 10 of 87 results
